JPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

JPMorgan Chase & Co. cut its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 3.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,712,990 shares of the biopharmaceutical company's stock after selling 63,155 shares during the period. JPMorgan Chase & Co. owned 3.00% of Agios Pharmaceuticals worth $76,108,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Caxton Associates LP raised its position in Agios Pharmaceuticals by 0.7% during the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company's stock valued at $1,615,000 after acquiring an additional 264 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 363 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Agios Pharmaceuticals by 6.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock worth $539,000 after purchasing an additional 688 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Agios Pharmaceuticals during the second quarter worth $37,000. Finally, Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter valued at about $40,000.

Agios Pharmaceuticals Trading Up 1.1 %

Shares of Agios Pharmaceuticals stock traded up $0.35 during trading on Friday, reaching $32.19. The company's stock had a trading volume of 881,852 shares, compared to its average volume of 767,276. The stock has a 50-day moving average price of $47.63 and a two-hundred day moving average price of $45.74. The stock has a market capitalization of $1.84 billion, a P/E ratio of 2.83 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a one year low of $20.96 and a one year high of $62.58.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AGIO. Royal Bank of Canada boosted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, November 9th. Leerink Partners cut Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Leerink Partnrs cut Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 27th. Finally, Raymond James reissued an "outperform" rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Agios Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.